Cagrilintide on TikTok: what the trial data actually shows

What did @theglow.lab actually say?

She described starting cagrilintide roughly a week ago, taking it once during her menstrual cycle because she was "real extra hungry," then experiencing significant fatigue and nausea days later. She's not entirely sure of the dosing schedule, guessing it's "one time a week or I think it's like one to five days or something like that." She frames nausea as expected and almost positive, because it's suppressing her appetite. She ends by asking followers for help managing her symptoms.

To her credit, she repeatedly flags this as personal experience, not medical advice. But the combination of uncertain dosing, stacking with unspecified compounds she calls "turds," and crowd-sourcing symptom management on TikTok is worth examining carefully.

Does the science back this up?

Nausea and fatigue are genuinely documented side effects of cagrilintide. The science supports that part. What's less clear is everything else she described.

Cagrilintide is a long-acting amylin analogue currently in late-stage clinical development, primarily studied as CagriSema, a fixed-ratio combination with semaglutide. In the SCALE-STEP 1 trial (Knop et al., 2023, NEJM), gastrointestinal side effects including nausea, vomiting, and diarrhea were among the most common adverse events, consistent with what she experienced. Fatigue has also appeared in trial data, though it tends to be less prominently reported than GI effects.

However, cagrilintide is not currently approved by the FDA for any indication. It is not a GLP-1 receptor agonist, despite this video being categorized under GLP-1 content. It works on amylin receptors and calcitonin receptors. That distinction matters for understanding its mechanism and risk profile.

What did they get wrong (or right)?

She got the nausea part right. Trials consistently show GI side effects are dose-dependent and common in the early weeks of amylin-based therapy. Credit where it's due.

What she got wrong is more concerning. Her dosing description is vague to the point of being medically useless: "one time a week or I think it's like one to five days." These are not interchangeable options. Cagrilintide in clinical trials is administered once weekly subcutaneously, and dosing intervals are not flexible in the way she implies.

She also mentions adding cagrilintide "on top of" other compounds she refers to casually as "turds," without naming them. Combining investigational peptides with other agents outside clinical supervision is a significant safety issue. No published data exists on the interaction profile of cagrilintide stacked with unspecified compounds in unsupervised settings.

Asking followers what they're "experiencing" and requesting crowd-sourced advice for managing nausea from an unapproved compound is not a research methodology. It is anecdote aggregation, which is a different thing entirely.

What should you actually know?

Cagrilintide is not approved by the FDA. It is not a GLP-1 agonist. It is an investigational amylin analogue that has shown promising weight-loss results in combination trials, but it is not available through any regulated pharmacy channel in the United States as an approved drug.

People obtaining it outside clinical trials are likely accessing compounded or gray-market peptide versions, which carry no guarantee of purity, concentration, or sterility. The FDA has issued warnings about compounded peptide products generally. This is not a minor caveat.

If you are experiencing nausea, fatigue, or appetite suppression from any compound and your response is to ask TikTok for help rather than a prescribing clinician, that is a gap in your care plan, not a research strategy. Nausea from amylin-pathway drugs can be managed with antiemetics, dose adjustments, and dietary changes, but those decisions require someone who knows your full medication list, not a comment section.

The OASIS 1 trial (Enebo et al., 2021, The Lancet) established the dose-escalation framework for cagrilintide monotherapy. Deviation from structured titration increases adverse event risk. "Low dose" is not a safe harbor if the escalation protocol is not being followed.